GADD45G and myeloproliferative neoplasm: We have shown that GADD45g is differentially expressed at low levels in patients with MPN, and cBioPortal analysis revealed that the rates of GADD45g gene mutation are extremely low in various myeloid malignancies (<0.5%), including AML, MPNs and MDSs (Supplementary Fig. 2a–c).